Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 2011. The report details a specific corporate action regarding share repurchases executed on June 17, 2011, pursuant to shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure changes related to share buybacks.
- Shares Repurchased: 1,600,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,282.5 pence per share; lowest price paid was 1,261 pence per share.
- Treasury Shares: Following cancellation, the Company holds 499,174,284 shares in Treasury.
- Treasury Ownership: Represents 8.84% of total issued share capital and 9.70% of total voting rights.
- Shares in Issue: 5,147,183,913 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of the Company's issued share capital through the cancellation of 1,600,000 repurchased shares. This action increased the proportion of Treasury shares held by the Company to 8.84% of total issued share capital.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Verify the total number of shares in issue (5,147,183,913) for calculating disclosure thresholds under Financial Services Authority rules.
- Confirm the updated Treasury share count (499,174,284) and its impact on voting rights (9.70%).
- Note that the repurchased shares were cancelled rather than held indefinitely.